APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Arterial Hypertension Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Arterial Hypertension Treatment Market Outlook and Growth Opportunities 2026

21 December 2025194 pages

Choose your research edition.

Industry ResearchPulmonary Arterial Hypertension Treatment Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Arterial Hypertension Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Arterial Hypertension Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Arterial Hypertension Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Arterial Hypertension Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pulmonary Arterial Hypertension Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Arterial Hypertension Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Arterial Hypertension Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Arterial Hypertension Treatment market include GSK, Teva Pharmaceuticals Inc, Eli Lilly and Company, Pfizer Inc, Bayer AG, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc and Actelion Inc, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pulmonary Arterial Hypertension Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Arterial Hypertension Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Arterial Hypertension Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pulmonary Arterial Hypertension Treatment market.

Pulmonary Arterial Hypertension Treatment Segment by Company

GSK

Teva Pharmaceuticals Inc

Eli Lilly and Company

Pfizer Inc

Bayer AG

United Therapeutic Corporation

SteadyMed Ltd

Gilead Sciences, Inc

Actelion Inc

Pulmonary Arterial Hypertension Treatment Segment by Type

Vasodilators

Endothelin Receptor Antagonists (ERA)

Phosphodiesterase 5 (PDE 5) Inhibitors

Soluble Guanylate Cyclase (SGC) Stimulator

Pulmonary Arterial Hypertension Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Pulmonary Arterial Hypertension Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pulmonary Arterial Hypertension Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pulmonary Arterial Hypertension Treatment key companies, revenue, market share, and recent developments.

3. To split the Pulmonary Arterial Hypertension Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pulmonary Arterial Hypertension Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Arterial Hypertension Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Arterial Hypertension Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Arterial Hypertension Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Arterial Hypertension Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Arterial Hypertension Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Arterial Hypertension Treatment industry.

Chapter 3: Detailed analysis of Pulmonary Arterial Hypertension Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pulmonary Arterial Hypertension Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pulmonary Arterial Hypertension Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Arterial Hypertension Treatment Industry Trends Table 2. Pulmonary Arterial Hypertension Treatment Industry Drivers Table 3. Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges Table 4. Pulmonary Arterial Hypertension Treatment Industry Restraints Table 5. Global Pulmonary Arterial Hypertension Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Arterial Hypertension Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pulmonary Arterial Hypertension Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Pulmonary Arterial Hypertension Treatment Company, Product Type & Application Table 10. Global Pulmonary Arterial Hypertension Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pulmonary Arterial Hypertension Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vasodilators Table 15. Significant Companies of Endothelin Receptor Antagonists (ERA) Table 16. Significant Companies of Phosphodiesterase 5 (PDE 5) Inhibitors Table 17. Significant Companies of Soluble Guanylate Cyclase (SGC) Stimulator Table 18. Global Pulmonary Arterial Hypertension Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pulmonary Arterial Hypertension Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pulmonary Arterial Hypertension Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Type (2021-2026) Table 22. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacies Table 24. Significant Companies of Online Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Global Pulmonary Arterial Hypertension Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pulmonary Arterial Hypertension Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Pulmonary Arterial Hypertension Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Application (2021-2026) Table 30. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Application (2027-2032) Table 31. Global Pulmonary Arterial Hypertension Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pulmonary Arterial Hypertension Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Region (2021-2026) Table 34. Global Pulmonary Arterial Hypertension Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Region (2027-2032) Table 36. Global Pulmonary Arterial Hypertension Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pulmonary Arterial Hypertension Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Pulmonary Arterial Hypertension Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global Pulmonary Arterial Hypertension Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Pulmonary Arterial Hypertension Treatment Sales Value Market Share by Country (2027-2032) Table 41. GSK Company Information Table 42. GSK Business Overview Table 43. GSK Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. GSK Pulmonary Arterial Hypertension Treatment Product Portfolio Table 45. GSK Recent Development Table 46. Teva Pharmaceuticals Inc Company Information Table 47. Teva Pharmaceuticals Inc Business Overview Table 48. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 50. Teva Pharmaceuticals Inc Recent Development Table 51. Eli Lilly and Company Company Information Table 52. Eli Lilly and Company Business Overview Table 53. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio Table 55. Eli Lilly and Company Recent Development Table 56. Pfizer Inc Company Information Table 57. Pfizer Inc Business Overview Table 58. Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 60. Pfizer Inc Recent Development Table 61. Bayer AG Company Information Table 62. Bayer AG Business Overview Table 63. Bayer AG Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio Table 65. Bayer AG Recent Development Table 66. United Therapeutic Corporation Company Information Table 67. United Therapeutic Corporation Business Overview Table 68. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio Table 70. United Therapeutic Corporation Recent Development Table 71. SteadyMed Ltd Company Information Table 72. SteadyMed Ltd Business Overview Table 73. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio Table 75. SteadyMed Ltd Recent Development Table 76. Gilead Sciences, Inc Company Information Table 77. Gilead Sciences, Inc Business Overview Table 78. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 80. Gilead Sciences, Inc Recent Development Table 81. Actelion Inc Company Information Table 82. Actelion Inc Business Overview Table 83. Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio Table 85. Actelion Inc Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Pulmonary Arterial Hypertension Treatment Product Image Figure 2. Global Pulmonary Arterial Hypertension Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Arterial Hypertension Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Arterial Hypertension Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vasodilators Image Figure 8. Endothelin Receptor Antagonists (ERA) Image Figure 9. Phosphodiesterase 5 (PDE 5) Inhibitors Image Figure 10. Soluble Guanylate Cyclase (SGC) Stimulator Image Figure 11. Global Pulmonary Arterial Hypertension Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pulmonary Arterial Hypertension Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacies Image Figure 15. Online Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. Global Pulmonary Arterial Hypertension Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pulmonary Arterial Hypertension Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Application (2021-2032) Figure 20. Global Pulmonary Arterial Hypertension Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America Pulmonary Arterial Hypertension Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Pulmonary Arterial Hypertension Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America Pulmonary Arterial Hypertension Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Vasodilators
  • Endothelin Receptor Antagonists (ERA)
  • Phosphodiesterase 5 (PDE 5) Inhibitors
  • Soluble Guanylate Cyclase (SGC) Stimulator
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Teva Pharmaceuticals Inc
  • Eli Lilly and Company
  • Pfizer Inc
  • Bayer AG
  • United Therapeutic Corporation
  • SteadyMed Ltd
  • Gilead Sciences, Inc
  • Actelion Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Arterial Hypertension Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Arterial Hypertension Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pulmonary Arterial Hypertension Treatment Market Dynamics
  1. 2.1 Pulmonary Arterial Hypertension Treatment Industry Trends
  2. 2.2 Pulmonary Arterial Hypertension Treatment Industry Drivers
  3. 2.3 Pulmonary Arterial Hypertension Treatment Industry Opportunities and Challenges
  4. 2.4 Pulmonary Arterial Hypertension Treatment Industry Restraints
3 Pulmonary Arterial Hypertension Treatment Market by Company
  1. 3.1 Global Pulmonary Arterial Hypertension Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Arterial Hypertension Treatment Company Ranking (2024-2026)
  4. 3.4 Global Pulmonary Arterial Hypertension Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Pulmonary Arterial Hypertension Treatment Company Product Type and Application
  6. 3.6 Global Pulmonary Arterial Hypertension Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pulmonary Arterial Hypertension Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pulmonary Arterial Hypertension Treatment Market by Type
  1. 4.1 Pulmonary Arterial Hypertension Treatment Type Introduction
  2. 4.1.1 Vasodilators
  3. 4.1.2 Endothelin Receptor Antagonists (ERA)
  4. 4.1.3 Phosphodiesterase 5 (PDE 5) Inhibitors
  5. 4.1.4 Soluble Guanylate Cyclase (SGC) Stimulator
  6. 4.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Type
  7. 4.2.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Type (2021-2032)
5 Pulmonary Arterial Hypertension Treatment Market by Application
  1. 5.1 Pulmonary Arterial Hypertension Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Application
  6. 5.2.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Pulmonary Arterial Hypertension Treatment Sales Value Share by Application (2021-2032)
6 Pulmonary Arterial Hypertension Treatment Regional Value Analysis
  1. 6.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Pulmonary Arterial Hypertension Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Pulmonary Arterial Hypertension Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Pulmonary Arterial Hypertension Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Arterial Hypertension Treatment Country-level Value Analysis
  1. 7.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pulmonary Arterial Hypertension Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pulmonary Arterial Hypertension Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pulmonary Arterial Hypertension Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pulmonary Arterial Hypertension Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pulmonary Arterial Hypertension Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Pulmonary Arterial Hypertension Treatment Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Teva Pharmaceuticals Inc
  8. 8.2.1 Teva Pharmaceuticals Inc Company Information
  9. 8.2.2 Teva Pharmaceuticals Inc Business Overview
  10. 8.2.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  12. 8.2.5 Teva Pharmaceuticals Inc Recent Developments
  13. 8.3 Eli Lilly and Company
  14. 8.3.1 Eli Lilly and Company Company Information
  15. 8.3.2 Eli Lilly and Company Business Overview
  16. 8.3.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product Portfolio
  18. 8.3.5 Eli Lilly and Company Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 Bayer AG
  26. 8.5.1 Bayer AG Company Information
  27. 8.5.2 Bayer AG Business Overview
  28. 8.5.3 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer AG Pulmonary Arterial Hypertension Treatment Product Portfolio
  30. 8.5.5 Bayer AG Recent Developments
  31. 8.6 United Therapeutic Corporation
  32. 8.6.1 United Therapeutic Corporation Company Information
  33. 8.6.2 United Therapeutic Corporation Business Overview
  34. 8.6.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product Portfolio
  36. 8.6.5 United Therapeutic Corporation Recent Developments
  37. 8.7 SteadyMed Ltd
  38. 8.7.1 SteadyMed Ltd Company Information
  39. 8.7.2 SteadyMed Ltd Business Overview
  40. 8.7.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product Portfolio
  42. 8.7.5 SteadyMed Ltd Recent Developments
  43. 8.8 Gilead Sciences, Inc
  44. 8.8.1 Gilead Sciences, Inc Company Information
  45. 8.8.2 Gilead Sciences, Inc Business Overview
  46. 8.8.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  48. 8.8.5 Gilead Sciences, Inc Recent Developments
  49. 8.9 Actelion Inc
  50. 8.9.1 Actelion Inc Company Information
  51. 8.9.2 Actelion Inc Business Overview
  52. 8.9.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Product Portfolio
  54. 8.9.5 Actelion Inc Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst